Where are we with RSV prophylaxis?

Area of Science:

• Pediatrics
• Infectious Diseases
• Public Health

Background:

• Respiratory syncytial virus (RSV) is a leading cause of respiratory illness and death in infants under 24 months.
• RSV infections exhibit predictable seasonal patterns, contributing significantly to childhood morbidity and mortality globally.
• Existing prophylactic measures, available since 1998, reduce hospitalizations in high-risk infants.

Purpose of the Study:

• To review the pathophysiology and risk factors associated with RSV infections in young children.
• To provide an overview of current pharmacological prophylaxis and prevention strategies for RSV.
• To highlight the accessibility challenges of existing RSV prophylaxis in resource-limited settings.

Main Methods:

• Literature review of RSV pathophysiology and epidemiology.
• Analysis of available RSV prophylaxis and prevention agents.
• Discussion of socioeconomic factors impacting access to care.

Main Results:

• RSV poses a substantial health burden, particularly for infants under two years old.
• Current pharmacological prophylaxis is effective but costly and infrastructure-dependent.
• Access to prophylaxis is severely limited in low- and middle-income countries where RSV mortality is highest.

Conclusions:

• Understanding RSV pathophysiology and risk factors is crucial for targeted prevention.
• The high cost and logistical demands of current prophylaxis hinder its widespread use, especially in developing nations.
• Further research and innovative strategies are needed to improve global access to RSV prevention and reduce childhood mortality.